Lido Advisors
BTAI icon

Lido Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Lido Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,040
Closed -$505K – 995
2021
Q3 		$505K Buy
1,040
+496
+91% +$218K 0.01% 593
2021
Q2 		$253K Buy
544
+210
+63% +$114K ﹤0.01% 780
2021
Q1 		$230K Sell
334
-119
-26% -$95.7K ﹤0.01% 757
2020
Q4 		$334K Buy
+453
New +$353K 0.01% 585

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lido Advisors's BTAI Position: Q4 2021 in Review

Lido Advisors sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 1,040 shares — an estimated $505K sold.

Lido Advisors first reported a position in BTAI in Q4 2020 and held it in 4 quarters. The position peaked at $505K in Q3 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Lido Advisors reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Lido Advisors sold 1,040 BioXcel Therapeutics shares in Q4 2021, an estimated $505K.
  • Lido Advisors first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 4 quarters.
  • Lido Advisors's BioXcel Therapeutics position peaked at $505K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Lido Advisors's 13F filing for Q4 2021, filed 15 Feb 2022.